Aarron Willingham

Affiliations: 
Merck & Co. 
Area:
biologics discovery and cell-based assays
Google:
"Aarron Willingham"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sukumar S, Wilson DC, Yu Y, et al. (2017) Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells. Cancer Research
Kenski DM, Butora G, Willingham AT, et al. (2012) siRNA-optimized Modifications for Enhanced In Vivo Activity. Molecular Therapy. Nucleic Acids. 1: e5
Chorn G, Klein-McDowell M, Zhao L, et al. (2012) Single-stranded microRNA mimics. Rna (New York, N.Y.). 18: 1796-804
Fucini RV, Haringsma HJ, Deng P, et al. (2012) Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Therapeutics. 22: 205-10
Kenski DM, Willingham AT, Haringsma HJ, et al. (2012) In vivo activity and duration of short interfering RNAs containing a synthetic 5'-phosphate. Nucleic Acid Therapeutics. 22: 90-5
Haringsma HJ, Li JJ, Soriano F, et al. (2012) mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic Acids Research. 40: 4125-36
Peacock H, Fucini RV, Jayalath P, et al. (2011) Nucleobase and ribose modifications control immunostimulation by a MicroRNA-122-mimetic RNA Journal of the American Chemical Society. 133: 9200-9203
Graveley BR, Brooks AN, Carlson JW, et al. (2011) The developmental transcriptome of Drosophila melanogaster. Nature. 471: 473-9
Cherbas L, Willingham A, Zhang D, et al. (2011) The transcriptional diversity of 25 Drosophila cell lines. Genome Research. 21: 301-14
Kenski DM, Cooper AJ, Li JJ, et al. (2010) Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Research. 38: 660-71
See more...